Oct 2017: A study performed by the Technical University of Munich, concluded that: “BioXmark provided a perfect basis for fractionated highprecision RT in particular, without any toxic side effects. Due to hardening artefacts, volumes of BioXmark exceeding 50 μl are not recommended in preclinical tumor mouse models. BioXmark position proved stable over 4 months and could be monitored by weekly CBCT. BioXmark helps to reproduce positioning during RT and enables an exact, unique reproducible fusion with the original treatment plan during image guidance. It therefore also minimizes the application of contrast agent in the fractionated RT setting“.